Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365851 | 0.96 | LMNA (0.62) | LMNAALDH1A1GAACYP1A2CYP2C9 | |
| SCHEMBL30689605 | 0.95 | LMNA (0.61) | LMNAALDH1A1GAACYP1A2CYP2C9 | |
| SCHEMBL1365559 | 0.95 | LMNA (0.61) | LMNAALDH1A1GAACYP1A2CYP2C9 | |
| SCHEMBL1365332 | 0.95 | LMNA (0.61) | LMNAALDH1A1GAACYP1A2CYP2C9 | |
| SCHEMBL1365966 | 0.95 | LMNA (0.61) | LMNAALDH1A1GAACYP1A2CYP2C9 | |
| SCHEMBL717926 | 0.94 | LMNA (0.68) | LMNAALDH1A1GAACYP1A2CYP2C9 | |
| SCHEMBL18281078 | 0.94 | LMNA (0.68) | LMNAALDH1A1GAACYP1A2CYP2C9 | |
| SCHEMBL57630 | 0.87 | LMNA (0.62) | LMNAALDH1A1GAACYP1A2CYP2C9 | |
| SCHEMBL1177430 | 0.87 | LMNA (0.62) | LMNAALDH1A1GAACYP1A2CYP2C9 | |
| SCHEMBL21814438 | 0.86 | LMNA (0.59) | LMNAALDH1A1GAACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | DKS CO. LTD. (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20260035407-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | DKS CO. LTD. (JP) | 2026-02-05 | — | — | US | disclosed |
| EP-4613282-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE | DKS Co. Ltd. (JP) | 2025-09-10 | — | — | EP | disclosed |
| EP-4613283-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN AND/OR INFLAMMATORY PAIN | DKS Co. Ltd. (JP) | 2025-09-10 | — | — | EP | disclosed |
| EP-4595973-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | DKS Co. Ltd. (JP) | 2025-08-06 | — | — | EP | disclosed |
| CN-120152726-A | Cyclic peptide derivative composition for treating or preventing central nervous system injury diseases | 第一工业制药株式会社 | 2025-06-13 | — | — | CN | disclosed |
| EP-4567042-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | DKS Co. Ltd. (JP) | 2025-06-11 | — | — | EP | disclosed |
| CN-119947740-A | Cyclic peptide derivative composition for treating or preventing ophthalmic diseases | 第一工业制药株式会社 | 2025-05-06 | — | — | CN | disclosed |
| CN-119731193-A | Cyclic peptide derivative, process for producing the same, and composition | 第一工业制药株式会社 | 2025-03-28 | — | — | CN | disclosed |
| US-20240368205-A1 | CHELATE COMPOUNDS | GE HEALTHCARE AS (NO) | 2024-11-07 | — | — | US | disclosed |
| US-20090163543-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2009-06-25 | — | — | US | disclosed |
| US-7507828-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2008066729-A2 | BORONIC ACID CONTAINING COMPOSITIONS | DARA BIOSCIENCES, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| EP-1644323-A4 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1644323-A2 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050032831-A1 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY | 2005-02-10 | — | — | US | disclosed |
| WO-2005007091-A2 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050014839-A1 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY | 2005-01-20 | — | — | US | disclosed |
| US-4990536-A | Immunopotentiator and spergualin-related compound therefor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1991-02-05 | — | — | US | disclosed |
| EP-0394684-A1 | Immunopotentiator and spergualin-related compound therefor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | ADCY3, GLP1R, PDE6C | LMNA 1658/4885ALDH1A1 2607/4885GAA 2434/4885 |
| US-20090163543-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | HDAC5, HDAC6, HDAC1 | LMNA 2137/4885ALDH1A1 376/4885GAA 123/4885 |
| US-20260035407-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | BDNF, VIP, CA3 | LMNA 3876/4885ALDH1A1 2934/4885GAA 4712/4885 |
| US-20240368205-A1 | CHELATE COMPOUNDS | SLC39A3, SLC39A11, MPI | LMNA 4483/4885ALDH1A1 3140/4885GAA 850/4885 |
| US-20050032831-A1 | Histone deacetylase inhibitors and methods of use thereof | HDAC5, HDAC6, HDAC1 | LMNA 2137/4885ALDH1A1 376/4885GAA 123/4885 |
| US-20050014839-A1 | Histone deacetylase inhibitors and methods of use thereof | HDAC5, HDAC6, HDAC1 | LMNA 1947/4885ALDH1A1 437/4885GAA 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.